A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs SGN-CD48A (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 07 Mar 2018 According to a Seattle Genetics media release, the first patient has been dosed in this trial.
- 08 Feb 2018 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
- 08 Feb 2018 Status changed from not yet recruiting to recruiting.